According to an SEC filing dated February 17, 2026, DAFNA Capital Management LLC reduced its stake in iShares Biotechnology ETF (NASDAQ:IBB) by 34,405 shares during the fourth quarter of 2025. The fund’s quarter-end IBB position value decreased by $3.31 million, a figure that factored in both share sales and price movement.
Following the sale, iShares Biotechnology ETF is comprised 2.67% of DAFNA Capital’s 13F reportable assets under management.
Top five holdings after the filing:
NASDAQ:RVMD: $48.15 million (11.3% of AUM)
NYSEMKT:XBI: $41.03 million (9.7% of AUM)
NYSEMKT:STXS: $31.47 million (7.4% of AUM)
NASDAQ:ATRC: $23.63 million (5.6% of AUM)
NASDAQ:CYTK: $23.57 million (5.5% of AUM)
As of February 17, 2026, shares of IBB were priced at $174.02, up 27.2% over the past year, with a one-year alpha of 15.84 percentage points versus the S&P 500.
Metric | Value |
|---|---|
AUM | 8.78 billion |
Price (as of market close 2/17/26) | $174.02 |
One-year total return | 22.07% |
Dividend yield | 0.22% |
iShares Biotechnology ETF provides investors with targeted exposure to the biotechnology sector by tracking a specialized industry index. The ETF track s the performance of the NASDAQ Biotechnology Index by investing at least 80% of assets in index components and substantially identical securities. It primarily invests in biotechnology and pharmaceutical equities, with exposure diversified across leading industry constituents.
The fund employs a passive investment approach, allocating the majority of assets to companies within the NASDAQ Biotechnology Index and maintaining flexibility to use derivatives for portfolio management. It is structured as a non-diversified ETF, with a focus on efficient index replication and liquidity management.
Its scale and liquidity offer institutional investors efficient access to a broad array of biotechnology equities, supporting portfolio diversification and sector-specific strategies.
The iShares Biotechnology ETF (IBB) offers exposure to the biotech sector through a market-cap-weighted portfolio focused on large, commercial-stage companies with approved products and established pipelines. This approach emphasizes industry leaders and reduces reliance on early-stage and higher-risk firms.
IBB’s performance is driven primarily by large-cap biotech earnings, product results, pipeline progress, and regulatory decisions. Since the fund is top-heavy, a small number of companies account for most returns. Although established businesses can reduce volatility compared to equal-weighted biotech funds, the sector remains sensitive to interest rates and investor risk appetite, which affect the valuation of growth-oriented healthcare stocks.
